Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
Eton Pharmaceuticals (ETON) reported record Q4 2024 product revenue of $11.6 million, marking a 59% increase over Q4 2023 and the 16th consecutive quarter of sequential growth. The company achieved several major milestones:
Key developments include the acquisition and January relaunch of Increlex, a pediatric endocrinology biologic, and the acquisition and March relaunch of Galzin for rare diseases. The company also licensed U.S. rights to Amglidia and reported positive pivotal study results for ET-600, with NDA submission planned for April 2025.
Financial highlights: Gross profit reached $6.5 million in Q4 2024, up from $3.6 million in Q4 2023. The company reported a reduced net loss of $0.6 million ($0.02 per share) compared to $2.3 million ($0.09 per share) in the prior year period. Cash position stood at $14.9 million as of December 31, 2024.
Eton Pharmaceuticals (ETON) ha riportato un fatturato record per il Q4 2024 di 11,6 milioni di dollari, segnando un aumento del 59% rispetto al Q4 2023 e il 16° trimestre consecutivo di crescita sequenziale. L'azienda ha raggiunto diversi traguardi importanti:
Sviluppi chiave includono l'acquisizione e il rilancio a gennaio di Increlex, un biologico per l'endocrinologia pediatrica, e l'acquisizione e il rilancio a marzo di Galzin per malattie rare. L'azienda ha anche ottenuto i diritti statunitensi per Amglidia e ha riportato risultati positivi da studi clinici decisivi per ET-600, con una richiesta di NDA programmata per aprile 2025.
Risultati finanziari: Il profitto lordo ha raggiunto 6,5 milioni di dollari nel Q4 2024, in aumento rispetto ai 3,6 milioni di dollari del Q4 2023. L'azienda ha riportato una perdita netta ridotta di 0,6 milioni di dollari (0,02 dollari per azione) rispetto ai 2,3 milioni di dollari (0,09 dollari per azione) del periodo dell'anno precedente. La posizione di cassa si è attestata a 14,9 milioni di dollari al 31 dicembre 2024.
Eton Pharmaceuticals (ETON) reportó ingresos récord de productos en el Q4 2024 de 11.6 millones de dólares, marcando un aumento del 59% en comparación con el Q4 2023 y el 16° trimestre consecutivo de crecimiento secuencial. La empresa alcanzó varios hitos importantes:
Los desarrollos clave incluyen la adquisición y relanzamiento en enero de Increlex, un biológico para endocrinología pediátrica, y la adquisición y relanzamiento en marzo de Galzin para enfermedades raras. La compañía también obtuvo los derechos en EE. UU. para Amglidia y reportó resultados positivos de estudios pivotal para ET-600, con una presentación de NDA planificada para abril de 2025.
Aspectos financieros: El beneficio bruto alcanzó 6.5 millones de dólares en el Q4 2024, en comparación con 3.6 millones de dólares en el Q4 2023. La compañía reportó una pérdida neta reducida de 0.6 millones de dólares (0.02 dólares por acción) en comparación con 2.3 millones de dólares (0.09 dólares por acción) en el mismo período del año anterior. La posición de efectivo se situó en 14.9 millones de dólares al 31 de diciembre de 2024.
Eton Pharmaceuticals (ETON)는 2024년 4분기 제품 수익이 1160만 달러로 기록적인 성과를 올렸으며, 이는 2023년 4분기 대비 59% 증가한 수치로, 16분기 연속 성장세를 이어가고 있습니다. 회사는 여러 주요 이정표를 달성했습니다:
주요 개발 사항으로는 소아 내분비학 생물학제인 Increlex의 인수 및 1월 재출시, 희귀 질환을 위한 Galzin의 인수 및 3월 재출시가 있습니다. 회사는 또한 Amglidia에 대한 미국 권리를 라이센스하고 ET-600에 대한 긍정적인 주요 연구 결과를 보고했으며, NDA 제출은 2025년 4월로 예정되어 있습니다.
재무 하이라이트: 2024년 4분기 총 이익은 650만 달러에 도달했으며, 이는 2023년 4분기의 360만 달러에서 증가한 수치입니다. 회사는 이전 연도 기간의 230만 달러(주당 0.09달러)와 비교하여 60만 달러의 순손실을 줄였으며(주당 0.02달러), 2024년 12월 31일 기준 현금 보유액은 1490만 달러로 나타났습니다.
Eton Pharmaceuticals (ETON) a annoncé un chiffre d'affaires record de 11,6 millions de dollars pour le Q4 2024, marquant une augmentation de 59 % par rapport au Q4 2023 et le 16e trimestre consécutif de croissance séquentielle. L'entreprise a atteint plusieurs jalons majeurs :
Les développements clés incluent l'acquisition et le relancement en janvier de Increlex, un produit biologique en endocrinologie pédiatrique, et l'acquisition et le relancement en mars de Galzin pour les maladies rares. L'entreprise a également obtenu les droits américains pour Amglidia et a rapporté des résultats positifs d'études pivot pour ET-600, avec une soumission de NDA prévue pour avril 2025.
Points financiers : Le bénéfice brut a atteint 6,5 millions de dollars au Q4 2024, contre 3,6 millions de dollars au Q4 2023. L'entreprise a signalé une perte nette réduite de 0,6 million de dollars (0,02 dollar par action) par rapport à 2,3 millions de dollars (0,09 dollar par action) au cours de la même période de l'année précédente. La position de trésorerie s'élevait à 14,9 millions de dollars au 31 décembre 2024.
Eton Pharmaceuticals (ETON) berichtete im Q4 2024 einen Rekordumsatz von 11,6 Millionen Dollar, was einem Anstieg von 59% im Vergleich zum Q4 2023 entspricht und das 16. aufeinanderfolgende Quartal mit sequenzieller Wachstumsrate darstellt. Das Unternehmen erreichte mehrere wichtige Meilensteine:
Zu den wichtigsten Entwicklungen gehören die Übernahme und der Relaunch von Increlex im Januar, einem biologischen Produkt für die pädiatrische Endokrinologie, sowie die Übernahme und der Relaunch von Galzin für seltene Krankheiten im März. Das Unternehmen hat auch die US-Rechte an Amglidia lizenziert und positive Ergebnisse aus entscheidenden Studien für ET-600 berichtet, mit einer NDA-Einreichung, die für April 2025 geplant ist.
Finanzielle Höhepunkte: Der Bruttogewinn erreichte 6,5 Millionen Dollar im Q4 2024, ein Anstieg von 3,6 Millionen Dollar im Q4 2023. Das Unternehmen berichtete von einem reduzierten Nettoverlust von 0,6 Millionen Dollar (0,02 Dollar pro Aktie) im Vergleich zu 2,3 Millionen Dollar (0,09 Dollar pro Aktie) im Vorjahreszeitraum. Die Liquiditätsposition belief sich zum 31. Dezember 2024 auf 14,9 Millionen Dollar.
- Record Q4 2024 product revenue of $11.6M, up 59% YoY
- 16 consecutive quarters of sequential revenue growth
- Gross profit increased to $6.5M from $3.6M YoY
- Net loss improved to $0.6M from $2.3M YoY
- Successful acquisition and relaunch of two commercial products (Increlex and Galzin)
- ET-400 patent granted, extending protection until 2043
- Positive ET-600 pivotal study results with patent protection until 2044
- Continued net loss of $0.6M in Q4 2024
- Increased G&A expenses to $6.7M from $4.6M YoY
- Relatively low cash position of $14.9M considering multiple product launches
Insights
Eton Pharmaceuticals delivered record Q4 2024 revenue of $11.6 million, representing impressive 59% year-over-year growth and marking their 16th consecutive quarter of sequential product sales increases. This sustained growth trajectory demonstrates strong commercial execution and validates their rare disease specialty focus.
The quarter featured multiple strategic acquisitions that substantially expand Eton's commercial portfolio. The Increlex acquisition (pediatric endocrinology biologic) appears particularly significant as early patient adoption is exceeding management expectations. The Galzin acquisition further strengthens their ultra-rare disease presence. These transactions diversify revenue streams while leveraging Eton's existing sales infrastructure.
Pipeline developments are equally substantial. ET-600's successful pivotal study enables an April NDA filing, while ET-400 awaits its May PDUFA date with launch inventory already manufactured. The company has wisely secured patent protection extending to 2043-2044 for these assets, creating long-term revenue potential.
Despite increased G&A expenses to support these launches, Eton significantly narrowed its net loss to $0.02 per share compared to $0.09 in Q4 2023. With $14.9 million in cash, the company appears positioned to execute its growth strategy while approaching profitability. The combination of strong organic growth, strategic acquisitions, and advancing pipeline candidates creates multiple near-term catalysts that could accelerate revenue growth throughout 2025.
Eton's portfolio transformation represents a strategic pivot toward higher-value rare disease assets with sustainable competitive advantages. The Increlex acquisition is particularly noteworthy – this complex biologic targets an ultra-rare pediatric endocrinology condition affecting approximately 200 children in the US. Such products typically command premium pricing with competition due to their complexity and small patient populations.
The positive pivotal study results for ET-600 significantly de-risk this asset ahead of its April NDA submission. Combined with the additional patent issuance (extending to 2044), this creates a potentially valuable commercial opportunity with substantial exclusivity. Similarly, ET-400's second patent strengthens its commercial potential should it receive approval on its May PDUFA date.
Eton's licensing of Amglidia (glyburide oral suspension) for neonatal diabetes aligns perfectly with their pediatric endocrinology focus. The product's established EU approval since 2018 reduces development risk for US commercialization. The FDA meeting scheduled for April will be important in determining the clinical pathway and timeline.
The undisclosed pipeline programs (ET-700 and ET-800) add further optionality. While details remain , the company's track record suggests these will target similar high-value rare disease opportunities. Eton has demonstrated disciplined pipeline execution, focusing on markets where patient needs remain underserved despite often having approved therapies available in suboptimal formulations.
Management to Hold Investor Day Conference Call Today at 10:00am ET
- Reported record product revenue of
$11.6 million in Q4 2024, an increase of59% over Q4 2023, representing the 16th straight quarter of sequential product sales growth - Closed the transformational acquisition of pediatric endocrinology biologic Increlex® and relaunched the product in January
- Acquired and relaunched ultra rare disease product Galzin®
- Licensed U.S. rights to late-stage pipeline candidate Amglidia®, further boosting the Company’s pediatric endocrinology pipeline
- Announced positive pivotal clinical study results for ET-600; preparing for an April 2025 NDA submission
- Manufactured ET-400 launch inventory in preparation for a potential approval on its PDUFA goal date of May 28
- Management to hold Investor Day conference call today at 10:00am ET to discuss its recent acquisitions and review its product portfolio, market opportunities, and 2025 and long-term financial outlook
DEER PARK, Ill., March 18, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2024.
“The fourth quarter of 2024 was the most transformational in Eton’s history. We closed the pivotal acquisition of Increlex, acquired another high-value rare disease product in Galzin, and boosted our product pipeline with the license of Amglidia and initiation of two exciting new internal development projects, ET-700 and ET-800. We completed all this while continuing to execute on our base business, delivering record product sales and our 16th straight quarter of sequential revenue growth,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
“We are poised for an acceleration of growth in 2025. Increlex was relaunched in January with our now fully dedicated pediatric endocrinology sales force and is already adding new patients at a pace well ahead of our expectations. Galzin was relaunched in March with our newly deployed metabolic sales force and has been well received by the Wilson disease community. Launch inventory for ET-400 has been manufactured and our team stands ready to launch the product within days of its PDUFA goal date of May 28, if approved. Finally, ET-600’s successful pivotal study results allow us to file an additional high-value NDA in the coming weeks.” concluded Brynjelsen.
Fourth Quarter and Recent Business Highlights
Delivered 16th straight quarter of sequential growth in product sales. Eton reported fourth quarter 2024 net sales of
Relaunched Increlex, which is tracking ahead of expectations. Increlex is a highly durable, complex biologic used for the treatment of an ultra-rare pediatric endocrinology condition that is estimated to impact approximately 200 children in the U.S. Eton closed the acquisition in late December and relaunched the product in the United States in January. The Company intends to leverage its existing sales team and relationships in the pediatric endocrinology community to promote the product and increase awareness of this underdiagnosed and undertreated condition. The launch has seen strong initial results, with numerous new patients added in January, February, and the first half of March.
Awarded second patent for ET-400 and preparing for potential launch. During the fourth quarter, Eton was granted an additional patent for ET-400 by the United States Patent & Trademark Office (USPTO). The patent, which expires in 2043, covers hydrocortisone oral liquid formulations and is expected to be listed in the FDA’s Orange Book upon approval. The Company has successfully manufactured launch quantities for the product and its sales and promotional campaigns are ready to go live. If approved on its May 28 Prescription Drug User Fee Act (PDUFA) goal date, the Company anticipates being in position to quickly launch the product.
Acquired and re-launched Galzin. In January, Eton added the ultra-rare disease commercial product Galzin to its metabolic portfolio. Seeing the need for improved patient experience, increased awareness, and broader access and affordability, the Company relaunched Galzin on March 3 with its newly deployed metabolic sales force and robust Eton Cares patient support service. The Eton Cares patient support program ensures patients can access Galzin with
Announced positive pivotal study results for ET-600 and the issuance of a patent. ET-600 passed its pivotal bioequivalence study, successfully demonstrating pharmacokinetic equivalence to the reference product. In addition, the Company was issued a patent covering the product’s proprietary formulation of desmopressin oral solution. The patent expires in 2044 and is expected to be listed in the FDA’s Orange Book upon the product’s approval. Eton is preparing to submit an NDA for ET-600 in April, which could allow for approval in the first quarter of 2026.
Disclosed two new internal development programs, ET-700 and ET-800. The Company has two new, high-value product candidates under development internally. More details regarding these previously undisclosed programs will be shared during Eton’s Investor Day conference call.
Acquired U.S. rights to Amglidia (glyburide oral suspension). Amglidia, which has been approved in the E.U. since 2018, is under development in the U.S. for the treatment of neonatal diabetes mellitus and has been granted Orphan Drug Designation by the FDA. Amglidia is a strong strategic fit with Eton’s existing pediatric endocrinology portfolio, and the Company is scheduled to meet with the FDA in April 2025 to discuss the product’s clinical pathway.
Fourth Quarter Financial Results
Net Revenue: Total net revenues for the fourth quarter of 2024 increased
Gross Profit: Gross profit for the fourth quarter of 2024 was
Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2024 were
General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2024 were
Net Loss: Net loss for the fourth quarter of 2024 was
Cash Position: As of December 31, 2024, Eton had cash and cash equivalents of
Conference Call and Webcast Information
As previously announced, Eton Pharmaceuticals will hold a virtual Investor Day and report fourth quarter 2024 financial results on Tuesday, March 18, 2025, beginning at 10:00 a.m. ET (9:00 a.m. CT).
To participate, please click here to register. An archived webcast will be available on the Investors section of Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
| Eton Pharmaceuticals, Inc. STATEMENTS OF OPERATIONS (In thousands, except per share amounts) | |||||||||||||||||
| For the three months ended | For the years ended | ||||||||||||||||
| (Unaudited) | |||||||||||||||||
| December 31, | December 31, | December 31, | December 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||
| Revenues: | |||||||||||||||||
| Licensing revenue | $ | — | $ | — | $ | 500 | $ | 5,500 | |||||||||
| Product sales and royalties, net | 11,647 | 7,313 | 38,511 | 26,142 | |||||||||||||
| Total net revenues | 11,647 | 7,313 | 39,011 | 31,642 | |||||||||||||
| Cost of sales: | |||||||||||||||||
| Licensing revenue | — | 1,000 | 270 | 1,000 | |||||||||||||
| Product sales and royalties | 5,171 | 2,683 | 15,330 | 9,581 | |||||||||||||
| Total cost of sales | 5,171 | 3,683 | 15,600 | 10,581 | |||||||||||||
| Gross profit | 6,476 | 3,630 | 23,411 | 21,061 | |||||||||||||
| Operating expenses: | |||||||||||||||||
| Research and development | (871 | ) | 1,047 | 3,255 | 3,322 | ||||||||||||
| General and administrative | 6,718 | 4,575 | 22,753 | 18,931 | |||||||||||||
| Total operating expenses | 5,847 | 5,622 | 26,008 | 22,253 | |||||||||||||
| Income (loss) from operations | 629 | (1,992 | ) | (2,597 | ) | (1,192 | ) | ||||||||||
| Other (expense) income: | |||||||||||||||||
| Interest and other (expense) income, net | (1,140 | ) | (17 | ) | (1,211 | ) | 503 | ||||||||||
| Loss before income tax expense | (511 | ) | (2,009 | ) | (3,808 | ) | (689 | ) | |||||||||
| Income tax expense | 87 | 247 | 15 | 247 | |||||||||||||
| Net loss | $ | (598 | ) | $ | (2,256 | ) | $ | (3,823 | ) | $ | (936 | ) | |||||
| Net loss per share, basic and diluted | $ | (0.02 | ) | $ | (0.09 | ) | $ | (0.15 | ) | $ | (0.04 | ) | |||||
| Weighted average number of common shares outstanding, basic and diluted | 26,136 | 25,741 | 25,895 | 25,645 | |||||||||||||
| Eton Pharmaceuticals, Inc. BALANCE SHEETS (in thousands, except share and per share amounts) | ||||||||
| December 31, | December 31, | |||||||
| 2024 | 2023 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 14,936 | $ | 21,388 | ||||
| Accounts receivable, net | 5,361 | 3,411 | ||||||
| Inventories, net | 15,232 | 911 | ||||||
| Prepaid expenses and other current assets | 5,492 | 1,129 | ||||||
| Total current assets | 41,021 | 26,839 | ||||||
| Property and equipment, net | 34 | 58 | ||||||
| Intangible assets, net | 34,881 | 4,739 | ||||||
| Operating lease right-of-use assets, net | 175 | 92 | ||||||
| Other long-term assets, net | 12 | 12 | ||||||
| Total assets | $ | 76,123 | $ | 31,740 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,167 | $ | 1,848 | ||||
| Current portion of long-term debt, net of discount | — | 5,380 | ||||||
| Accrued Medicaid rebates | 6,866 | 3,627 | ||||||
| Accrued liabilities | 8,914 | 5,386 | ||||||
| Total current liabilities | 19,947 | 16,241 | ||||||
| Long-term debt, net of discount and including accrued fees | 29,811 | — | ||||||
| Operating lease liabilities, net of current portion | 107 | 22 | ||||||
| Other long-term liabilities | 1,830 | — | ||||||
| Total liabilities | 51,695 | 16,263 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity | ||||||||
| Common stock, | 27 | 26 | ||||||
| Additional paid-in capital | 132,294 | 119,521 | ||||||
| Accumulated deficit | (107,893 | ) | (104,070 | ) | ||||
| Total stockholders’ equity | 24,428 | 15,477 | ||||||
| Total liabilities and stockholders’ equity | $ | 76,123 | $ | 31,740 | ||||
| Eton Pharmaceuticals, Inc. STATEMENTS OF CASH FLOWS (In thousands) | ||||||||||||||||
| For the three months ended | For the years ended | |||||||||||||||
| (Unaudited) | ||||||||||||||||
| December 31, | December 31, | December 31, | December 31, | |||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Cash flows from operating activities | ||||||||||||||||
| Net loss | $ | (598 | ) | $ | (2,256 | ) | $ | (3,823 | ) | $ | (936 | ) | ||||
| Adjustments to reconcile net loss to net cash from operating activities: | ||||||||||||||||
| Stock-based compensation | 782 | 750 | 3,165 | 3,137 | ||||||||||||
| Depreciation and amortization | 355 | 325 | 1,146 | 901 | ||||||||||||
| Non-cash lease expense | 17 | 17 | 70 | 67 | ||||||||||||
| Debt discount amortization | 1,039 | 27 | 1,109 | 117 | ||||||||||||
| Changes in operating assets and liabilities, net of impact of product acquisitions: | — | — | ||||||||||||||
| Accounts receivable | (939 | ) | 84 | (3,118 | ) | (1,559 | ) | |||||||||
| Inventories | (34 | ) | 140 | (1,061 | ) | (354 | ) | |||||||||
| Prepaid expenses and other assets | (3,520 | ) | (655 | ) | (3,349 | ) | 94 | |||||||||
| Accounts payable | 1,482 | 105 | 2,318 | 53 | ||||||||||||
| Accrued Medicaid rebates | (1,181 | ) | 476 | 3,239 | 2,818 | |||||||||||
| Accrued liabilities | 2,043 | 1,374 | 1,484 | 2,477 | ||||||||||||
| Other non-current assets and liabilities | 38 | — | 38 | — | ||||||||||||
| Net cash from operating activities | (516 | ) | 387 | 1,218 | 6,815 | |||||||||||
| Cash from investing activities | ||||||||||||||||
| Purchases of property and equipment | (12 | ) | — | (26 | ) | — | ||||||||||
| Acquisition of business | (30,000 | ) | — | (30,000 | ) | — | ||||||||||
| Purchase of product licensing rights | (8,369 | ) | (775 | ) | (10,237 | ) | (775 | ) | ||||||||
| Net cash from investing activities | (38,381 | ) | (775 | ) | (40,263 | ) | (775 | ) | ||||||||
| Cash flows from financing activities | ||||||||||||||||
| Net proceeds from the issuance of long-term debt | 25,309 | — | 25,309 | — | ||||||||||||
| Repayment of long-term debt | — | (385 | ) | (1,155 | ) | (1,155 | ) | |||||||||
| Common stock issued in private placement offering | 7,000 | — | 7,000 | — | ||||||||||||
| Proceeds from stock option exercises | 1,015 | — | 1,191 | 148 | ||||||||||||
| Payment of tax withholding related to net share settlement of stock option exercises | — | — | — | (180 | ) | |||||||||||
| Employee stock purchase plan | 108 | 91 | 248 | 229 | ||||||||||||
| Stock warrant exercises | — | — | — | — | ||||||||||||
| Net cash from financing activities | 33,432 | (294 | ) | 32,593 | (958 | ) | ||||||||||
| Change in cash and cash equivalents | (5,465 | ) | (682 | ) | (6,452 | ) | 5,082 | |||||||||
| Cash and cash equivalents at beginning of period | 20,401 | 22,070 | 21,388 | 16,305 | ||||||||||||
| Cash and cash equivalents at end of period | $ | 14,936 | $ | 21,388 | $ | 14,936 | $ | 21,388 | ||||||||
| Supplemental disclosures of cash flow information | ||||||||||||||||
| Cash paid for interest | $ | 140 | $ | 204 | $ | 665 | $ | 842 | ||||||||
| Cash paid for income taxes | $ | (99 | ) | $ | 247 | $ | 82 | $ | 247 | |||||||
| Supplemental disclosures of non-cash investing and financing activities: | ||||||||||||||||
| Debt issuance costs | $ | 386 | $ | — | $ | 386 | $ | — | ||||||||
| Fair value of warrants issued in connection with debt agreement | $ | — | $ | — | $ | 1,171 | $ | — | ||||||||
| Right-of-use assets obtained in exchange for lease liabilities | $ | 66 | $ | — | $ | 219 | $ | 29 | ||||||||
FAQ
What was Eton Pharmaceuticals' revenue growth in Q4 2024 compared to Q4 2023?
When will Eton Pharmaceuticals submit the NDA for ET-600?
What is the PDUFA date for Eton's ET-400 product?
How many new products did ETON acquire or relaunch in Q4 2024 and early 2025?
What was Eton Pharmaceuticals' net loss per share in Q4 2024?
